Immix Biopharma (IMMX) Competitors $1.70 -0.01 (-0.58%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$1.72 +0.03 (+1.47%) As of 03/28/2025 05:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMMX vs. CKPT, LFVN, NMRA, CRGX, AMRN, TNGX, KOD, ACRS, RZLT, and FDMTShould you be buying Immix Biopharma stock or one of its competitors? The main competitors of Immix Biopharma include Checkpoint Therapeutics (CKPT), LifeVantage (LFVN), Neumora Therapeutics (NMRA), CARGO Therapeutics (CRGX), Amarin (AMRN), Tango Therapeutics (TNGX), Kodiak Sciences (KOD), Aclaris Therapeutics (ACRS), Rezolute (RZLT), and 4D Molecular Therapeutics (FDMT). These companies are all part of the "pharmaceutical products" industry. Immix Biopharma vs. Checkpoint Therapeutics LifeVantage Neumora Therapeutics CARGO Therapeutics Amarin Tango Therapeutics Kodiak Sciences Aclaris Therapeutics Rezolute 4D Molecular Therapeutics Checkpoint Therapeutics (NASDAQ:CKPT) and Immix Biopharma (NASDAQ:IMMX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, community ranking, institutional ownership, earnings, media sentiment and analyst recommendations. Do institutionals and insiders hold more shares of CKPT or IMMX? 22.0% of Checkpoint Therapeutics shares are owned by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are owned by institutional investors. 2.1% of Checkpoint Therapeutics shares are owned by company insiders. Comparatively, 48.9% of Immix Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is CKPT or IMMX more profitable? Checkpoint Therapeutics' return on equity of 0.00% beat Immix Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Checkpoint TherapeuticsN/A N/A -659.07% Immix Biopharma N/A -102.68%-80.89% Which has better earnings and valuation, CKPT or IMMX? Immix Biopharma has lower revenue, but higher earnings than Checkpoint Therapeutics. Immix Biopharma is trading at a lower price-to-earnings ratio than Checkpoint Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCheckpoint Therapeutics$47K4,197.56-$51.85M-$1.84-2.20Immix BiopharmaN/AN/A-$15.43M-$0.77-2.21 Does the media refer more to CKPT or IMMX? In the previous week, Checkpoint Therapeutics had 1 more articles in the media than Immix Biopharma. MarketBeat recorded 5 mentions for Checkpoint Therapeutics and 4 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 1.56 beat Checkpoint Therapeutics' score of 0.08 indicating that Immix Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Checkpoint Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immix Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts rate CKPT or IMMX? Checkpoint Therapeutics currently has a consensus target price of $4.33, suggesting a potential upside of 7.26%. Immix Biopharma has a consensus target price of $7.00, suggesting a potential upside of 311.76%. Given Immix Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Immix Biopharma is more favorable than Checkpoint Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Checkpoint Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Immix Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in CKPT or IMMX? Checkpoint Therapeutics received 170 more outperform votes than Immix Biopharma when rated by MarketBeat users. However, 100.00% of users gave Immix Biopharma an outperform vote while only 67.04% of users gave Checkpoint Therapeutics an outperform vote. CompanyUnderperformOutperformCheckpoint TherapeuticsOutperform Votes18167.04% Underperform Votes8932.96% Immix BiopharmaOutperform Votes11100.00% Underperform VotesNo Votes Which has more risk and volatility, CKPT or IMMX? Checkpoint Therapeutics has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Comparatively, Immix Biopharma has a beta of 0.26, meaning that its share price is 74% less volatile than the S&P 500. SummaryImmix Biopharma beats Checkpoint Therapeutics on 9 of the 15 factors compared between the two stocks. Remove Ads Get Immix Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMMX vs. The Competition Export to ExcelMetricImmix BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$46.76M$6.90B$5.63B$7.84BDividend YieldN/A2.77%5.33%4.01%P/E Ratio-2.007.2623.6018.74Price / SalesN/A218.62388.2390.77Price / CashN/A65.6738.1734.64Price / Book2.106.386.894.23Net Income-$15.43M$142.34M$3.20B$247.47M7 Day Performance-5.56%-5.15%-3.06%-2.29%1 Month Performance-4.49%-7.55%1.52%-5.81%1 Year Performance-44.63%-11.06%9.37%-0.96% Immix Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMMXImmix Biopharma2.7324 of 5 stars$1.70-0.6%$7.00+311.8%-44.6%$46.76MN/A-2.009Earnings ReportNews CoverageCKPTCheckpoint Therapeutics2.1714 of 5 stars$4.05-0.5%$4.33+7.0%+97.1%$197.77M$47,000.00-2.2010Earnings ReportShort Interest ↓News CoverageLFVNLifeVantage3.7843 of 5 stars$15.56+0.6%$30.50+96.0%+138.3%$195.29M$212.15M27.79260NMRANeumora Therapeutics3.1935 of 5 stars$1.20+6.2%$10.14+745.2%-92.5%$194.38MN/A-0.64108CRGXCARGO Therapeutics3.1376 of 5 stars$4.20+0.5%$15.00+257.1%-81.3%$193.42MN/A-0.99116Analyst RevisionAMRNAmarin0.9792 of 5 stars$0.46+1.6%N/A-50.6%$190.76M$228.61M-5.16360Short Interest ↓Positive NewsTNGXTango Therapeutics1.7997 of 5 stars$1.74-1.1%$12.33+608.8%-81.5%$188.11M$42.07M-1.4790Short Interest ↑KODKodiak Sciences3.9982 of 5 stars$3.52+7.3%$8.00+127.3%-44.7%$185.24MN/A-0.9690Earnings ReportUpcoming EarningsNews CoverageGap DownACRSAclaris Therapeutics2.1862 of 5 stars$1.70+6.3%$11.67+586.3%+28.2%$183.46M$18.72M-3.27100Short Interest ↑RZLTRezolute2.7969 of 5 stars$3.03-0.7%$24.38+704.5%+14.9%$183.42MN/A-2.4840News CoverageFDMT4D Molecular Therapeutics2.811 of 5 stars$3.93+0.3%$30.63+679.3%-88.6%$181.97M$37,000.00-1.38120 Remove Ads Related Companies and Tools Related Companies Checkpoint Therapeutics Competitors LifeVantage Competitors Neumora Therapeutics Competitors CARGO Therapeutics Competitors Amarin Competitors Tango Therapeutics Competitors Kodiak Sciences Competitors Aclaris Therapeutics Competitors Rezolute Competitors 4D Molecular Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMMX) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredPartner with Elon Musk on Project Colossus… Before May 1stEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon’s ‘Strike Squad’ sends these 9 stocks soaring?Elon Musk's DOGE 'strike squad' just revealed it's speeding up the rollout of a radical technology across the ...Altimetry | SponsoredDoomed: These 50 Stocks Will Die Under Trump’s MAGA policies.Remember Kodak? Sears? Circuit City? They all failed to adapt to the changing times. Now, history is abo...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immix Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immix Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IMMX Stock Free IMMX Stock Alerts